Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. - Wikidata - wikimedia - TriplyDB

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

http://www.wikidata.org/entity/Q39973557

about

The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior Peptide-based probes for targeted molecular imaging.Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.Peptides and peptide hormones for molecular imaging and disease diagnosis Orexin-1 receptor mediates the increased food and water intake induced by intracerebroventricular injection of the stable somatostatin pan-agonist, ODT8-SST in rats.Radiolabeled regulatory peptides for imaging and therapy Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in rats.Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior.Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion LC/MS evaluation of metabolism and membrane transport of bombesin peptides.Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2.Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study Design and development of molecular imaging probes.Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues Prospective of ⁶⁸Ga-radiopharmaceutical development.Illuminating somatostatin analog action at neuroendocrine tumor receptors Orexigenic response to tail pinch: role of brain NPY(1) and corticotropin releasing factor receptors.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Receptor-mediated tumor targeting based on peptide hormones.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Radiopharmaceutical development of radiolabelled peptides.Molecular imaging probes derived from natural peptides.On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats.Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications.Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

P2860

Q28085083-C45AB626-4EA9-4D6A-8375-47FDB0B427F2 Q33526620-E1C013A1-ADCE-46CA-9D0A-5908A93EE140 Q33576472-C822E739-2B6C-4E86-9CAE-FBC143BD97A2 Q33846924-BCBFFA14-0275-418C-837A-434B48254DAF Q33896001-93614097-65C2-4D22-BF14-AD29706DA867 Q33941027-B02948E6-2411-4A36-8CB3-449D8A0595C0 Q34110022-9A0E479B-25ED-4640-8A76-B2F84BFCE81B Q34132339-6B9F2288-4CB8-4251-BA56-6FA4A47F01F3 Q34295828-240C8288-BAF8-400E-AE85-EBB7D3523EC9 Q34480762-2EE4C733-E038-41A2-BA60-7CCBE48DB61A Q34490275-CF0718F2-6CB1-4728-8C30-89FA2AEECFA2 Q34514544-8A6F911C-9D4A-43B6-A162-E685A001B4AC Q35159637-15E94468-B34D-4D34-A45F-C237B02BCAAB Q35268662-3B8A266A-37EE-42B9-BF59-30D774C7F2FB Q36125639-7D47D1C4-0788-48CE-90EA-C6BE469D8E89 Q36785137-1E090B7E-2CDA-4AAA-9448-33F93957DC57 Q36788491-5B9436A8-06FC-48E7-88E8-EEF67DA26BCD Q37152806-724CCC9E-0CC2-44E0-91EB-8B2FAD592DD2 Q37426662-AAC4EE96-75CB-4DFE-8057-F396E08751EE Q37435222-E10DFC7F-4777-4C9F-8F63-F7D9DD790480 Q37443562-140ADFD7-D1B8-4545-A995-BF9CCB30F94C Q37578127-EDE1B7AB-0CC1-4C55-8BA2-E63CA3984880 Q37579225-0054A455-74E2-4C22-8017-F97D995EB361 Q37641368-8F345ADB-7D7D-4111-B228-CE85E78F3AC6 Q37731335-86F66334-2FBD-408A-BC11-34CA83202D62 Q37975101-CC5C315C-50A7-42C5-B822-4FFBD892C8E4 Q37990399-2B7A38DA-EEA7-4596-9BF2-061CD2323D42 Q38748846-930F68E4-61E1-46C9-8F22-DBEEA06E97A3 Q39544807-F6AFFD6C-F7A0-4F2B-BA2B-FCCB9FC64870 Q40084135-54098F44-7446-4927-A40F-287443AFF1C5 Q40098290-2190032E-ECA1-43CF-A1CC-B886595B72B1 Q40124645-208A3CB0-0420-4232-8636-9CFFE22B9071 Q41847481-8416B081-E4C2-442D-B7BE-4F61205D232F Q42519592-431D9C18-91E2-4045-ACC0-FAC80C07F2B4 Q45996806-ACE343A7-E111-4FD0-9EB8-3DBEDE360C56 Q52580539-3695472F-411C-4748-9FBF-26325AA9FB3E Q57144951-03654CDB-1494-455C-A158-98AF821458D5 Q58803952-089FFB35-925A-4B83-B0F8-59052E20B8E2

P2860

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

http://www.wikidata.org/entity/Q39973557

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Design and in vitro characteri ...... s suitable for radiotargeting.

@en

Design and in vitro characteri ...... s suitable for radiotargeting.

@nl

type

label

Design and in vitro characteri ...... s suitable for radiotargeting.

@en

Design and in vitro characteri ...... s suitable for radiotargeting.

@nl

prefLabel

Design and in vitro characteri ...... s suitable for radiotargeting.

@en

Design and in vitro characteri ...... s suitable for radiotargeting.

@nl

P1433

Q39973557-2CBB29D5-42A5-4005-A3B7-6FD7ABF5A981

P1476

Q39973557-3E35AA5D-AF3A-4E1E-9441-1A5FF95290A3

P2093

Q39973557-0D703B8D-42A2-4AC5-B995-7B04453A6978

Q39973557-48EA52C5-6150-47DC-BFDB-6DB6A1E77C67

Q39973557-57132F6E-1852-46A8-A60D-9B066AA17970

Q39973557-77A245E0-0111-450E-ABAE-4C4000521D30

Q39973557-85146337-8B12-46FD-9F78-C4C0632E8D1B

Q39973557-CE6DA439-780A-458C-9796-733FFA6B9DA3

P2860

Q39973557-12CE611E-539A-4E78-B00A-94468F26664C

Q39973557-14B75C6D-B12B-4618-B784-C04FA3F9E594

Q39973557-2D59CB63-0E31-4891-9AD1-4103F701CE1C

Q39973557-314B4C42-6557-443F-A801-8A1AA15DEA30

Q39973557-346E5DEC-3AB3-4406-A07E-3A9E139CF634

Q39973557-39887D11-5A95-495E-AB3A-F768A849664A

Q39973557-520A98DA-15BB-42F5-98D2-82BE2B534ABE

Q39973557-53919B7D-B56B-4087-838F-7C4ABC0F9DF0

Q39973557-5919E75A-DEB8-496D-B4EA-9FCEC4DFD8CF

Q39973557-5DA3BAD5-24EB-4820-880F-AA548180E042

P304

Q39973557-AA8A849D-A954-4611-BBF0-2167F0210187

P31

Q39973557-5F2B8865-539C-41F1-8442-E3B41DDED756

P356

Q39973557-F693EFED-7B4D-4B82-81BD-226E3B34BADC

P407

Q39973557-587DF0F0-AAF1-44B3-BC8B-2974DEC0851E

P433

Q39973557-BFB64C06-70D2-4CAD-8DCB-7C08B7E6B8E1

P478

Q39973557-222624E9-4051-454A-801D-211B3F3FA164

P50

Q39973557-D941E230-D8DE-420B-BC96-D98B548F2168

P577

Q39973557-5F8DDB4A-BD7E-47EF-A349-870FABFACA8B

P5875

Q39973557-A58E8523-0E95-49C1-8163-8AACCC5D8D38

P698

Q39973557-75F6D397-7E56-480D-B54A-EB9289DD19AA

P932

Q39973557-BA5026BF-0B7C-4E74-AE13-2267481720B7

P356

P1433

Journal of Medicinal Chemistry

P1476

Design and in vitro characteri ...... s suitable for radiotargeting.

@en

P2093

Beatrice Waser

http://www.w3.org/2001/XMLSchema#string

Helmut R Maecke

http://www.w3.org/2001/XMLSchema#string

Jean E Rivier

http://www.w3.org/2001/XMLSchema#string

Judith Erchegyi

http://www.w3.org/2001/XMLSchema#string

Renzo Cescato

http://www.w3.org/2001/XMLSchema#string

Véronique Piccand

http://www.w3.org/2001/XMLSchema#string

P2860

(R)-tert-Butoxycarbonylamino-fluorenylmethoxycarbonyl-glycine from (S)-benzyloxycarbonyl-serine or from papain resolution of the corresponding amide or methyl ester.

Receptor targeting for tumor localisation and therapy with radiopeptides.

Peptide receptor imaging and therapy.

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

SST3-selective potent peptidic somatostatin receptor antagonists.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

The radionuclide molecular imaging and therapy of neuroendocrine tumors.

Nuclear imaging of neuroendocrine tumours.

Neuroendocrine tumors. Peptide receptor radionuclide therapy.

P304

4030-4037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM701618Q

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Jean Claude Reubi

P577

2008-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5313186

http://www.w3.org/2001/XMLSchema#string

P698

18543899

http://www.w3.org/2001/XMLSchema#string

P932

2789649

http://www.w3.org/2001/XMLSchema#string